Overview

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Status:
Completed

Trial end date:
2017-01-31

Target enrollment:

Participant gender:

Summary

The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant gliomas. The safety of these drug combinations will also be studied. The goal of this Phase II part of this clinical research study is to learn if bevacizumab when given with or without vorinostat can help to control malignant gliomas. The safety of these drug combinations will also be studied.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborators:

Baylor Health Care System
Brain Tumor Trials Collaborative
Columbia University
Genentech, Inc.
Henry Ford Health System
M.D. Anderson Cancer Center
Merck Sharp & Dohme Corp.
MUSC Hollings Cancer Center
NorthShore University HealthSystem
Northwestern University Feinberg School of Medicine
Ohio State University Wexner Medical Center
Rush University Medical Center
Texas Oncology-Austin
The Cleveland Clinic
UF Health Cancer Center at Orlando Health
Univeristy of Washington Medical Center
University of North Carolina, Chapel Hill
University of Utah Health System
University of Washington
Washington University School of Medicine

Treatments:

Bevacizumab
Vorinostat